CLINICAL PHARMACOLOGY APPROACH TO THE USE OF ANTIARRHYTHMIC DRUGS

Admin bo'lib kirish (www.admin.slib.uz)

Tizim sinov (TEST) rejimida ishlamoqda! Murojat uchun @slib_support

Eski talqinga o'tish link

27 декабр 2024

Asosiy til:Ingliz

CLINICAL PHARMACOLOGY APPROACH TO THE USE OF ANTIARRHYTHMIC DRUGS

Fan yo'nalishi:

676ef1584bc93.pdf

PDF

Eurasian Journal of Academic Research

Maqola chop etish see more

MAQOLA ANNOTATSIYASI

This article explores the clinical pharmacology of antiarrhythmic drugs, focusing on their classification, mechanisms of action, and clinical applications in managing cardiac arrhythmias. The pharmacokinetics and pharmacodynamics of key drug classes, including sodium channel blockers, beta-blockers, potassium channel blockers, and calcium channel blockers, are discussed. Special attention is given to the selection of antiarrhythmic agents based on the type of arrhythmia, patient-specific factors, and potential side effects. The article also highlights the role of evidence-based approaches in optimizing therapy and minimizing proarrhythmic risks

MUALIFLAR

Teglar

# beta-blockers# cardiac arrhythmias# Antiarrhythmic drugs# clinical pharmacology# sodium channel blockers

Maqolani baholang

0

0 ta

Maqola idintifikatorlari

ROI:

https://eroi.uz/11.0201/A1224-0187

DOI:

Mavjud emas

Foydalanilgan adabiyotlar

1.Vatutin N.T., Taradin G.G., Gritsenko Yu.P. Lung damage as a complication of amiodarone therapy. Pulmonology. 2016; 26 (2): 246-253. doi:10.18093/0869-1.0189-2016-26-2-246-253.2.Vatutin N.T., Shevelyok A.N., Degtyareva A.E., Taradin G.G., Gritsenko Yu.P., Vasilenko I.V. Development of lung damage during amiodarone administration. Cardiology. 2016;8: 93-96. doi:10.18565/cardio.2016.8.93-96.3.Allen LaPointe N.M., Lokhnygina Y., Sanders G.D. [et al.] Adherence to guideline recommendations for antiarrhythmic drugs in atrial fibrillation. Am Heart J 2013;166:871-8.4.Hohnloser S.H., Crijns H.J., van Eickels M. [et al.] Effect of dronedarone on cardiovascular events in atrial fibrillation. N Engl J Med. 2009;360: 668-78. doi:10.1056/NEJMoa0803778.5.Dan G.A., Martinez-Rubio A., Agewall S. [et al.] Antiarrhythmic drugs-clinical use and clinical decision making: a consensus document from the European Heart Rhythm Association (EHRA) and European Society of Cardiology (ESC) Working Group on Cardiovascular Pharmacology, endorsed by the Heart Rhythm Society (HRS), Asia-Pacific Heart Rhythm Society (APHRS) and International Society of Cardiovascular Pharmacotherapy (ISCP). Europace. 2018;20(5): 731-732. doi:10.1093/europace/eux373.